Atypical Chronic Inflammatory ANCA-Positive Deforming Arthritis After Cocaine-Levamisole Exposure.

BACKGROUND/OBJECTIVE: Immunostimulatory drugs including immune checkpoint inhibitors and levamisole can induce inflammatory disease including vasculitis, rashes, tissue necrosis, and arthritis. METHODS: This prospective cohort study determined the 5-year outcomes of cocaine-levamisole-induced inflammatory disease as to outcomes and survival. Thirty-one consecutive cocaine-levamisole autoimmune patients and 45 primary vasculitis patients were characterized as to clinical differentiating features, antineutrophil cytoplasmic antibody (ANCA) status, treatment, the presence of acute and chronic arthritis, and 5-year outcome. RESULTS: Seventy-one percent (22/31) of cocaine-levamisole vasculopathy cases were ANCA positive (86% p-ANCA and 14% c-ANCA), whereas 53% (23/45) of the primary vasculitis were ANCA positive (p = 0.04). The ANCA-positive cocaine-levamisole cohort at onset were characterized by younger age (45 ± 12 vs 53 ± 14 years, p = 0.04), superficial skin necrosis (82% vs 54%, p = 0.036), depressed complement C3 (27% vs 4%, p = 0.33), antiphospholipid antibodies (50% vs 4%, p < 0.001), neutropenia (18% vs 0%, p = 0.044), and elevated antimyeloperoxidase (MPO) antibody levels (100% vs 67%, p < 0.001). Chronic cocaine-levamisole disease was characterized by severe cicatrical deformities of the face and extremities (45.5% vs 8.3%, p = 0.005). Arthralgias (71% vs 82%, p = 0.19) and acute arthritis (33% vs 32%, p = 0.25) were similar between the 2 groups. However, a substantial proportion cocaine-levamisole-induced autoimmune patients (18% vs 0%, p = 0.045) developed a chronic deforming inflammatory arthritis that was rheumatoid factor, anti-cyclic-citrillinated antibody antibody, and HLA-B27 negative, but p-ANCA-and MPO antibody positive. CONCLUSIONS: Patients exposed to cocaine-levamisole may develop serious chronic sequelae including cicatrical cutaneous and facial deformities and an atypical seronegative, p-ANCA and MPO antibody-positive, HLA-B27-negative chronic deforming inflammatory arthritis.

US for detecting renal calculi with nonenhanced CT as a reference standard.

PURPOSE: To determine the sensitivity and specificity of ultrasonography (US) for detecting parenchymal and renal pelvis calculi and to establish the accuracy of US for determining the size and number of calculi. MATERIALS AND METHODS: A total of 123 US and computed tomographic (CT) examinations were compared retrospectively for the presence of renal calculi. The sensitivity of US was determined for individual calculi and at least one calculus per examination. Retrospective findings were compared with the original US interpretation. The sizes of calculi in longest axis were compared on US and CT images, and the US detection of calculi in the left and right kidneys was compared. The use of US for detecting the full extent of calculus burden was evaluated in patients with multiple calculi. RESULTS: US depicted 24 of 101 calculi identified at CT, yielding a sensitivity of 24% and a specificity of 90%. There was no substantial difference for the detection of calculi in the right and left kidneys. The sensitivity of US for any calculi in a patient was 44%, equal to that of the original US interpretation. US enabled identification of 39% of patients with multiple calculi and demonstrated all calculi in 17% of these patients. The mean size of calculi detected with US was 7.1 mm +/- 1.2 (95% CI); 73% of calculi not visualized at US were less than 3.0 mm in size. Calculus size based on US and CT measurements was concordant in 79% of cases and differed by a mean of 1.5 mm +/- 0.7. CONCLUSION: US is of limited value for detecting renal calculi.